Dr. Davies discusses data from CheckMate-274 study of nivolumab in urothelial carcinoma


"I think that for patients that have high-risk features after cystectomy, they absolutely should be on nivolumab. I don't think that's a controversial statement anymore," says Benjamin J. Davies, MD.

In this video, Benjamin J. Davies, MD, discusses findings from the study, Disease-free survival with longer follow-up from the CheckMate-274 trial of adjuvant nivolumab in patients after surgery for high-risk muscle-invasive urothelial carcinoma, which was presented at the 2022 American Urological Association Annual Meeting in New Orleans, Louisiana. Davies is a professor of urology at the University of Pittsburgh School of Medicine, chief of urology at UPMC Shadyside, and program director of the Urologic Oncology Fellowship.

Related Videos
Orange pill bottle with loose pills spilling out | Image Credit: © Antonio Rodriguez - stock.adobe.com
3d rendered illustration of bladder cancer | Image Credit: © SciePro - stock.adobe.com
Heather L. Huelster, MD, answers a question during a Zoom video interview
3d rendered illustration of kidney cancer | Image Credit: © SciePro - stock.adobe.com
Bottle of white pills | Image Credit: © leighannef - stock.adobe.com
Related Content
© 2023 MJH Life Sciences

All rights reserved.